Investor News

Acorda Therapeutics® Strengthens Patent Portfolio on the Neuregulins

07/11/2005

Hawthorne, NY July 11, 2005 – Acorda Therapeutics® announced today that it has been awarded a new patent on its neuregulins products. This patent covers compositions of matter for the NRG2 family of growth factors as well as methods of production for NRG2. The addition of this patent broadens Acorda's existing neuregulins portfolio. NRG2 has potential applications in multiple sclerosis, spinal cord injury, Parkinson's disease and chronic heart failure. The Company plans to continue to file patents in support of the neuregulins program.

About Neuregulins
The neuregulins are a class of naturally-occurring protein growth factors, which have multiple effects on the nervous system and potential therapeutic applications in central nervous system disorders and cardiac indications. Growth factors are proteins that bind to receptors on the cell surface, with the primary result of activating cellular survival, proliferation and/or differentiation. Many growth factors are quite versatile, stimulating cellular division in numerous different cell types; while others are specific to a particular cell-type.

About Acorda Therapeutics
Acorda Therapeutics, a privately-held biotechnology company, is developing therapies for spinal cord injury (SCI), multiple sclerosis (MS) and related nervous system disorders. The Company's marketed products include ZANAFLEX®CAPSULES (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical-stage product is Fampridine-SR, which is being developed for both MS and SCI. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.